| |
EQ-5D-3L at 6 months (mean)
|
EQ-5D-3L at 12 months (mean)
|
Difference between 12 and 6 months EQ-5D-3L (95% CI)
|
Effect size (Cohen’s D)a
|
n
|
% reporting 3L score increase
|
|---|
|
3L-VAS
|
|
Improved
|
0.80
|
0.90
|
0.10 (0.02 to 0.17)
|
0.81*
|
13
|
69
|
|
No change
|
0.85
|
0.87
|
0.01 (− 0.02 to 0.06)
|
0.12
|
32
|
41
|
|
Worsened
|
0.75
|
0.74
|
− 0.01 (− 0.12 to 0.09)
|
− 0.05
|
18
|
28
|
| |
EQ-5D-5L at 6 months (mean)
|
EQ-5D-5L at 12 months (mean)
|
Difference between 12 and 6 months EQ-5D-5L (95% CI)
|
Effect size (Cohen’s D)
|
n
|
% reporting 5L score increase
|
|---|
|
5L-VAS
|
|
Improved
|
0.75
|
0.87
|
0.11 (0.02 to 0.20)
|
0.78
|
13
|
62
|
|
No change
|
0.82
|
0.85
|
0.03 (− 0.01 to 0.06)
|
0.16
|
32
|
38
|
|
Worsened
|
0.73
|
0.69
|
− 0.04 (− 0.14 to 0.06)
|
− 0.14
|
18
|
39
|
- aCohen’s D effect sizes of between 0.2 and 0.5 are considered small, 0.5 and 0.8 moderate and > 0.8 large. *p < 0.05
